There was a decreasing trend in the treatment gap between each anti-vascular endothelial growth factor (anti-VEGF) injection for both wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) patients from 2011 to 2019. Here, VEGFA is linked to wet macular degeneration.